Safety Study of PPI-1019 in Patients With Mild-Moderate Alzheimer's Disease
Status:
Completed
Trial end date:
2005-06-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, double-blind, inpatient study followed by outpatient,
placebo-controlled, single-dose, dose-escalation evaluation of the safety and tolerability of
PPI-1019 in patients with mild-moderate Alzheimer's disease (AD). Up to 12 sequential cohorts
of 8 patients (6 active and 2 placebo) will be given a single PPI-1019 dose intravenously
(IV) over 1 minute in order to determine a maximum tolerated dose (MTD). The MTD will be the
dose immediately below the not-tolerated dose.